Cinacalcet: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
NICE (England), PBAC (Australia) and TLV (Sweden) recommended or restricted cinacalcet, while AWMSG (Wales) and SMC (Scotland) did not recommend it.
On the same population the two systems disagree outright: NICE (England) recorded restricted in TA117, while SMC (Scotland) recorded not recommended for “Secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis therapy”.
The file has been open for more than a decade: 16.9 years separate the first record, 9 May 2005 at SMC (Scotland), from the most recent, 14 Apr 2022 at CONITEC (Brazil).
CONITEC (Brazil) changed its position: not recommended on 16 Oct 2013, recommended by 14 Apr 2022, after a resubmission.
No assessment is on file from HAS (France), CIPM (Spain) and G-BA (Germany), each among the eight highest-volume agencies here.
Not every gap is a refusal: for cinacalcet, 3 submissions were never made — an outcome set by the company rather than the assessor.
The programme is broad: 8 distinct indication wordings are recorded for cinacalcet by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
1 of these 24 records carries a year of decision but no day, so any interval quoted here is approximate to within a year.
SMC (Scotland) was first to assess cinacalcet, on 9 May 2005; PBAC (Australia) did not open a file until 2019 — an unusually long tail of 14.2 years between the earliest and latest system to look at it.
The record arrives in waves: 6 separate years each carry two or more decisions, spread across 12 years in total.
4 of the 7 agencies here assessed cinacalcet more than once, PHARMAC (New Zealand) most often at 9 entries — repeat review is the norm for this molecule rather than the exception.
7 of the 18 agencies in this archive hold a record for cinacalcet.
The full ledger for cinacalcet reads 12 recommended, 6 not recommended, 3 non-submission and 2 not assessed, with 1 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| CONITEC (Brazil) | 14 Apr 2022 | Tratamento de pacientes com hiperparatireoidismo secundário à doença renal crônica estágio 5D. | incorporated into SUS | source |
| SMC (Scotland) | 9 Mar 2020 | Secondary hyperparathyroidism (HPT) Treatment of secondary HPT in adult patients with end-stage renal disease (ESRD) on maintenance dialysis therapy. Treatment of seconda… | not recommended | source |
| PBAC (Australia) | 2019 | Chronic kidney disease (CKD) | The PBAC recommended the Section 100 (Highly Specialised Drugs Program) Authority Required… | source |
| PHARMAC (New Zealand) | 5 Nov 2015 | Parathyroid disorders, non-malignant, any cause, without symptomatic hypercalcaemia | PTAC advice: Decline | source |
| AWMSG (Wales) | 24 May 2005 | Reduction of hypercalcaemia in patients with parathyroid carcinoma | outside AWMSG criteria | source |
19 further decisions for cinacalcet, across 6 agencies, are not shown here. They link to 17 further source documents.
Related molecules
- etelcalcetide — same ATC class H05B — Calcium homeostasis
- nirmatrelvir / ritonavir — also decided by CONITEC in 2022Q2
- blinatumomab — also decided by CONITEC in 2022Q2
- sevelamer — also decided by CONITEC in 2022Q2
- baricitinib — also decided by CONITEC in 2022Q2
- tacrolimus — also decided by CONITEC in 2015Q3
Coverage: 24 decisions for cinacalcet from 7 agencies, 2005 to 2022. Data to 7 Sep 2026. ATC class H05B — Calcium homeostasis. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.